Janssen to Progress Collaboration with ViiV Healthcare to Develop the First Long Acting Two Drug ...

(Source: Johnson & Johnson) 5bdf0770-87c8-4b68-992a-859cfe2ae0b0.pdf January 7, 2016 Janssen to Progress Collaboration with ViiV Healthcare to Develop the First Long Acting Two Drug Injectable Regimen for Treatment of HIV Infection CORK, Ireland, January 7, 2016 /PRNewswire/ -- Results from ongoing phase IIb Week 32 study show that if successfully developed and approved, people living with HIV could potentially maintain viral suppression  Janssen Sciences Ireland UC (Janssen), today formalized its collaboration with ViiV Healthcare on phase III development and commercialization of a two drug regimen of two long acting, all-injectable formulations of rilpivirine (a non-nucleoside reverse...